| A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC) (NCT01600339) | Rambam Health Care Campus | 2012-05-01 |
| Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract (NCT01844947) | Dr Anders Ullén | 2012-05-01 |
| Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy (NCT01437488) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2012-02-16 |
| B7-Family Score in Urothelial Carcinoma (NCT06169904) | Shanghai Zhongshan Hospital | 2012-01-25 |
| First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma (NCT01524991) | Hoosier Cancer Research Network | 2012-01-01 |
| Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction (NCT01366144) | National Cancer Institute (NCI) | 2011-06-20 |
| DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma (NCT01353222) | Dendreon | 2011-06-01 |
| DNA Methylation and Arsenic-associated Urothelial Carcinoma (NCT01360723) | China Medical University Hospital | 2011-05-01 |
| TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma (NCT01328574) | National Cancer Institute (NCI) | 2011-03-01 |
| Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma (NCT01261728) | Memorial Sloan Kettering Cancer Center | 2010-12-14 |
| First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma (NCT01215136) | Matthew Galsky | 2010-12-01 |
| A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy (NCT01234519) | AEterna Zentaris | 2010-11-01 |
| Prospective Multicentric Evaluation of a Bladder Preservation Strategy (NCT01093066) | Centre Hospitalier Universitaire de Saint Etienne | 2010-09-21 |
| Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma (NCT01071928) | Hoosier Cancer Research Network | 2010-06-01 |
| Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy (NCT01042795) | University of Michigan | 2009-09-01 |
| Aristolochic Acid-DNA Adduct in Urothelial Carcinoma in Taiwan (NCT00867633) | National Taiwan University Hospital | 2009-03-01 |
| Arsenic Methylation Enzymes, Cigarette Metabolites, DNA Repair Enzymes, Inflammatory Factors and Urothelial Carcinoma (NCT00854464) | National Taiwan University Hospital | 2008-08-01 |
| Pemetrexed and Cisplatin in Advanced Urothelial Carcinoma (NCT01490437) | Asan Medical Center | 2008-07-01 |
| Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection (NCT00362713) | Bristol-Myers Squibb | 2007-03-01 |
| Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma (NCT00588666) | Memorial Sloan Kettering Cancer Center | 2006-05-01 |
| An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG (NCT06443944) | CG Oncology, Inc. | |
| Named Patient Program for Mitomycin for Pyelocalyceal Solution (NCT05494411) | UroGen Pharma Ltd. | |